Business Context and Reporting Period
Company: CURIS, INC. (CRIS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Curis is a biotechnology company focused on developing emavusertib (CA-4948), an oral inhibitor of IRAK4 and FLT3, for hematologic malignancies. The company holds an exclusive license for emavusertib through a collaboration with Aurigene Discovery Technologies Limited. In November 2025, Curis sold its interest in Curis Royalty LLC, including the Erivedge intellectual property and Genentech license agreement, effectively ending its royalty revenue stream from that asset.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenues, net | $9.4 million | $10.9 million |
| Net Loss | $(7.6) million | $(43.4) million |
| Research & Development Expenses | $28.3 million | $38.6 million |
| General & Administrative Expenses | $14.0 million | $16.8 million |
| Cash and Cash Equivalents (Dec 31, 2025) | $5.1 million | $20.0 million |
| Accumulated Deficit | $(1.25) billion | $(1.24) billion |
| Net Cash Used in Operating Activities | $(27.2) million | $(39.6) million |
Note: The 2025 Net Loss includes a one-time non-cash gain of $27.2 million related to the release of liability from the sale of future royalties associated with the Erivedge asset sale.
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 13% to $9.4 million, primarily due to the sale of the Erivedge asset in Q4 2025, which terminated future royalty entitlements from Genentech.
- Expense Reduction: Operating expenses decreased significantly. R&D expenses fell 27% to $28.3 million, and G&A expenses fell 16% to $14.0 million, driven by lower employee-related, clinical, and professional costs.
- Asset Sale Impact: The company recognized a $27.2 million gain on the release of liability related to the sale of future royalties, which substantially reduced the reported net loss compared to the prior year's $43.4 million loss.
- Liquidity Position: Cash and cash equivalents dropped from $20.0 million in 2024 to $5.1 million in 2025. However, in January 2026 (subsequent to period end), the company completed a PIPE financing raising approximately $18.6 million.
Guidance, Outlook, and Risks
Going Concern Warning
Management has identified conditions and events that raise substantial doubt about the company's ability to continue as a going concern. Despite the January 2026 financing, the company does not have sufficient cash on hand to support operations beyond 12 months from the filing date. Continued funding is required to advance emavusertib.
Clinical Development Outlook
- TakeAim Lymphoma: Ongoing Phase 1/2 study of emavusertib in combination with ibrutinib for relapsed/refractory primary central nervous system lymphoma (PCNSL). Regulatory discussions with the FDA and EMA suggest the current single-arm study could support an accelerated approval pathway (NDA in U.S., CMA in Europe).
- TakeAim CLL: Recently initiated Phase 2 study of emavusertib in combination with zanubrutinib for frontline chronic lymphocytic leukemia (CLL). Dosing expected in H1 2026, with initial data expected in Q4 2026.
- AML: Monotherapy and combination studies in Acute Myeloid Leukemia are substantially complete; further development depends on additional funding.
Key Risks
- Capital Requirements: The company faces substantial difficulties raising capital. Failure to secure additional funding could force delays or elimination of the emavusertib program.
- Regulatory Uncertainty: Approval is not guaranteed. The company relies on accelerated approval pathways which require confirmatory studies.
- Competition: Intense competition exists in IRAK4, FLT3, and BTK inhibitor spaces from large pharmaceutical companies.
- Nasdaq Compliance: The company recently regained compliance with Nasdaq listing requirements following a deficiency notice regarding market value of listed securities, but remains under a one-year discretionary panel monitor.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $18.6 million raised in January 2026 combined with existing cash to fund operations through the next 12 months.
- Erivedge Sale Finality: Confirm that no residual royalty revenue or liability remains from the Genentech/Erivedge agreement following the November 2025 sale.
- Clinical Milestones: Monitor enrollment and dosing timelines for the TakeAim CLL study and data readouts for the TakeAim Lymphoma study.
- Regulatory Feedback: Track the status of confirmatory study design alignment with the FDA and EMA for emavusertib.
- Dilution Risk: Review the terms of the January 2026 PIPE financing, specifically the warrant exercise prices ($0.75) and potential dilution from the conversion of Series B Preferred Stock.